Radioligand Therapy and PET Imaging for Prostate and Neuroendocrine Cancers
This community develops targeted radiopharmaceuticals for treating and imaging advanced prostate cancer and neuroendocrine tumors, focusing on the delivery of therapeutic radionuclides to specific cellular receptors.
The work centers on the development and clinical application of radioligand therapy, specifically using Lutetium-177 and Actinium-225 to target the prostate-specific membrane antigen (PSMA) and somatostatin receptors. A substantial portion of the research involves PSMA PET imaging for diagnosis and treatment planning in metastatic castration-resistant prostate cancer. The community also investigates peptide receptor radionuclide therapy for neuroendocrine tumors, utilizing Gallium-68 and Indium-111 for diagnostic SPECT and PET imaging. Studies frequently address bone metastases, preclinical evaluation of new radiotracers, and the integration of imaging with systemic treatments like androgen deprivation therapy.
The largest share of this community's output is found in Lutetium research, accounting for 17.5% of all Lutetium research tracked, and Radium research, representing 7.9% of that element's literature. The community includes 34,754 papers, publishing primarily in the European Journal of Nuclear Medicine and Molecular Imaging, the Journal of Nuclear Medicine, and Nuclear Medicine and Biology.
Recent work includes phase 3 trials evaluating Lutetium-177-PSMA-617 in metastatic hormone-sensitive prostate cancer, standardized reporting consensus for PSMA PET/CT, and reviews of targeted radionuclide therapy mechanisms.